Akebia Therapeutics, Inc.
AKBAUS売上高
$236M
百万USD
営業利益
$23M
百万USD
純利益
$-5M
百万USD
ROE
-16.4%
最新FY
EPS
$-0.02
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $52M | $-70M | - |
| FY2021 | Q2 | $53M | $-83M | $-0.51 |
| FY2021 | Q3 | $49M | $-60M | $-0.34 |
| FY2021 | FY | $214M | $-283M | $-1.70 |
| FY2022 | Q1 | $62M | $-62M | $-0.35 |
| FY2022 | Q2 | $127M | $29M | $0.15 |
| FY2022 | Q3 | $49M | $-52M | $-0.28 |
| FY2022 | FY | $292M | $-94M | $-0.52 |
| FY2023 | Q1 | $40M | $-26M | $-0.14 |
| FY2023 | Q2 | $56M | $-11M | $-0.06 |
| FY2023 | Q3 | $42M | $-14M | $-0.08 |
| FY2023 | FY | $195M | $-52M | $-0.28 |
| FY2024 | Q1 | $33M | $-18M | $-0.09 |
| FY2024 | Q2 | $44M | $-9M | $-0.04 |
| FY2024 | Q3 | $37M | $-20M | $-0.10 |
| FY2024 | FY | $160M | $-69M | $-0.33 |
| FY2025 | Q1 | $57M | $6M | $0.03 |
| FY2025 | Q2 | $62M | $0M | $0.00 |
| FY2025 | Q3 | $59M | $1M | $0.00 |
| FY2025 | FY | $236M | $-5M | $-0.02 |
| FY2026 | Q1 | $54M | $-9M | $-0.03 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $208M | $335M | $295M | $214M | $292M | $195M | $160M | $236M |
| 営業利益 | $-136M | $-80M | $-178M | $-286M | $-376M | $-265M | $-81M | $-46M | $-50M | $23M |
| 純利益 | $-136M | $-77M | $-144M | $-280M | $-383M | $-283M | $-94M | $-52M | $-69M | $-5M |
| 総資産 | $300M | $364M | $997M | $771M | $644M | $526M | $356M | $242M | $221M | $377M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $68M | $119M | $636M | $395M | $248M | $76M | $5M | $-31M | $-49M | $33M |
| 営業CF | - | - | $-97M | $-257M | $-110M | $-253M | $-73M | $-23M | $-41M | $68M |
| EPS | - | - | - | - | - | $-1.70 | $-0.52 | $-0.28 | $-0.33 | $-0.02 |
| BPS | $1.75 | $2.47 | $5.43 | $3.04 | $1.61 | $0.42 | $0.03 | $-0.15 | $-0.21 | $0.12 |
| ROE | -199.3% | -64.5% | -22.6% | -70.8% | -154.9% | -369.9% | -1801.6% | 169.8% | 141.1% | -16.4% |